Contract manufacturer Capsugel is pouring millions into three facilities around the world, looking to bolster its bandwidth in soft gelatin and liquid-fill hard capsules.
PPD is working to get therapeutic area experts into its highest offices, poaching UCB's former head of immunology to lead its efforts in the field.
Quintiles has finalized a deal for CRO Novella Clinical, snapping up its client base of emerging drug and device developers.
U.K. contract manufacturer Aesica is counting on a bullish market for solid dose diabetes drugs, and the company has poured $48 million into one of its plants to meet the demand.
Catalent has partnered up with Supernus Pharmaceuticals to supply the generics maker's extended-release epilepsy drug, a product the companies say has a chance to snag a share of a big market.
CRO inVentiv Health has struck up two deals to expand its offerings, launching a policy-focused joint venture and a partnership aimed at clinical trial site selection.
Indiana-headquartered CRO Harlan Laboratories has expanded its specialty research production facility in Southern Europe, offering contract breeding service for sponsors who need animal models for clinical trials.
In-transition drugmaker Columbia Laboratories is looking to cash in on the high-growth market for outsourced drug development, snatching up U.K. CRO Molecular Profiles for $25 million.
Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.
Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.
Italian contract researcher CROS NT has landed in the U.S., snapping up medical device-focused CRO Stat-Tech.
Two weeks after agreeing to become part of CRO giant Quintiles, Novella Clinical is promoting from within to prepare for future growth.
MPI Research has partnered up with two imaging outfits to open a state-of-the-art center for drug developers, and the trio has broken ground on what it calls a first-of-its-kind facility.
Twenty-two years after founding the Albany contract developer, AMRI CEO Thomas D'Ambra will retire from his post on New Year's Eve, leaving the helm as the company works to get out from regulatory scrutiny and grow revenue.
Contract manufacturer Patheon is still reaping the benefits of its high-dollar buyout of Banner Pharmacaps, wrapping up the integration process and reporting a 30.4% leap in quarterly profits.
CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.
Contract manufacturer Capsugel has signed a deal to buy Oregon's Bend Research, planning to fold that company's oral drug delivery technology into its growing innovative dosing business.
The FDA is adding teeth to rules requiring some drugmakers to conduct pediatric trials of new therapies, and the toughened enforcement could create an opportunity for CROs.
Despite concerns about slashed R&D budgets, overexpansion and consolidation, the titans of the CRO business are still posting double-digit growth, clocking $13.6 billion in 2012, according to a report.